Reuters logo
10 months ago
BRIEF-Atara Bio receives positive opinion from EMA on orphan drug designation for its CMV-CTL product candidate
October 11, 2016 / 12:11 PM / 10 months ago

BRIEF-Atara Bio receives positive opinion from EMA on orphan drug designation for its CMV-CTL product candidate

Oct 11 (Reuters) - Atara Biotherapeutics Inc

* Atara Bio receives positive opinion from EMA on orphan drug designation for allogeneic cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTL) for treatment of CMV infection in patients with impaired immune systems Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below